Mahwah, New Jersey, November 27, 2024: Glenmark Pharmaceuticals Inc., USA
(Glenmark) is pleased to announce the launch1 of Travoprost Ophthalmic Solution USP,
0.004% (Ionic Buffered Solution). Glenmark’s Travoprost Ophthalmic Solution USP, 0.004%
is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z®2
Ophthalmic Solution USP, 0.004% of Sandoz, Inc.
According to IQVIATM sales data for the 12-month period ending September 2024, the
Travatan Z® Ophthalmic Solution USP, 0.004% market3 achieved annual sales of approximately $66.2 million*.
Commenting on the launch, Jim Brown, Senior Vice President, Sales & Marketing said,
“We are excited to announce the launch of Travoprost Ophthalmic Solution USP, 0.004%,
growing our portfolio of prescription ophthalmic products. This addition highlights our
commitment to meeting market needs and providing high-quality solutions for our
customers.”
Glenmark’s current portfolio consists of 200 products authorized for distribution in the U.S.
marketplace and 51 ANDA’s pending approval with the U.S. FDA. In addition to these
internal filings, Glenmark continues to identify and explore external development
partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.